Immuron (IMRN) Accounts Payables (2016 - 2025)
Immuron's quarterly Accounts Payables came in at $15294.3 in Q3 2025, down 28.39% year-on-year from $21358.5 in Q3 2024, and down 97.63% quarter-over-quarter from $644701.1 in Q2 2025.
Immuron has reported Accounts Payables for 10 years, with the latest figure at $15294.3 in Q3 2025.
- For the quarter ending Q3 2025, Accounts Payables fell 28.39% year-over-year to $15294.3; the trailing twelve-month figure through Sep 2025 stood at $15294.3 (down 28.39% YoY), and the FY2025 full-year result was $15294.3, down 28.39% from the prior year.
- Accounts Payables for Q3 2025 stood at $15294.3, down from $644701.1 in the prior quarter.
- The five-year high for Accounts Payables was $842036.5 in Q4 2024, with the low at $7584.9 in Q2 2021.
- Average Accounts Payables over 5 years is $406757.3, with a median of $490086.1 recorded in 2024.
- Year-over-year, Accounts Payables jumped 23098.63% in 2021 and tumbled 98.58% in 2023.
- Tracing IMRN's Accounts Payables over 5 years: stood at $552563.4 in 2021, then soared by 38.04% to $762732.0 in 2022, then plunged by 98.58% to $10838.7 in 2023, then soared by 7668.8% to $842036.5 in 2024, then tumbled by 98.18% to $15294.3 in 2025.
- The last three Accounts Payables figures came in at $15294.3 (Q3 2025), $644701.1 (Q2 2025), and $842036.5 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | 15,294.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 15,294.34 |
| Jun 30, 2025 | 644,701.05 |
| Dec 31, 2024 | 842,036.48 |
| Sep 9, 2024 | 21,358.52 |
| Jun 30, 2024 | 427,608.70 |
| Dec 31, 2023 | 10,838.70 |
| Sep 28, 2023 | 781,835.96 |
| Aug 30, 2023 | 11,927.69 |
| Jun 30, 2023 | 797,199.62 |
| Dec 31, 2022 | 762,732.01 |
| Aug 31, 2022 | 807,311.55 |
| Jun 30, 2022 | 11,608.93 |
| Dec 31, 2021 | 552,563.44 |
| Jun 30, 2021 | 7,584.94 |
| Dec 31, 2020 | 2,381.88 |
| Sep 1, 2020 | 384,397.00 |
| Jun 30, 2020 | 251,941.72 |
| Dec 31, 2019 | 3,843.97 |
| Jun 30, 2019 | 764,858.99 |
| Dec 31, 2018 | 689,326.00 |
| Sep 27, 2018 | 504,501.36 |
| Aug 30, 2018 | 689,326.00 |
| Jun 30, 2018 | 521,845.23 |
| Dec 31, 2017 | 1.01 Mn |
| Sep 28, 2017 | 1.05 Mn |
| Aug 31, 2017 | 1.33 Mn |
| Jun 30, 2017 | 525,494.16 |
| Dec 31, 2016 | 1.50 Mn |